Nasdaq

Vivos Therapeutics Announces Positive Clinical Trial Results for Pediatric Obstructive Sleep Apnea Treatment Using Patented DNA Appliance

Vivos Therapeutics, Inc. has announced the publication of positive results from a multicenter clinical trial on its Daytime-Nighttime Appliance (DNA) for treating obstructive sleep apnea (OSA) in ...
Seeking Alpha

Vivos Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea Treatment

LITTLETON, Colo., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (VVOS), a leading medical device and technology company specializing in the development and commercialization of highly ...
Nasdaq

Vivos Therapeutics Receives FDA 510(k) Clearance of its Flagship DNA Oral Appliance for Treatment of Obstructive Sleep Apnea

LITTLETON, Colo., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for ...
Seeking Alpha

Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring

Vivos is poised to disrupt the very significant pediatric obstructive sleep apnea (OSA) market with new FDA clearance and new strategic marketing and distribution model Vivos’ DNA appliance now ...
Benzinga.com

Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In Children

On Wednesday, the FDA granted 510(k) clearance to Vivos Therapeutics, Inc.’s (NASDAQ:VVOS) flagship oral medical device, which is used to treat moderate to severe obstructive sleep apnea (OSA) and ...